Assignee
SHUTTLE PHARMACEUTICALS INC
US·8 granted patents·5 pending applications·0 citations·filing 2016–2025
Top patents by PatentIndex Score
13 records- 0183US12357650B2Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorlylase inhibitors in combination with radiationSHUTTLE PHARMACEUTICALS INC·Filed 2023·Granted Jul 15, 2025·0 cites·14 claims
- 0278US2025302857A1Methods And Compositions For Cancer Therapies That Include Delivery Of Halogenated Thymidines And Thymidine Phosphorylase Inhibitors In Combination With RadiationSHUTTLE PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 0377US2023302034A1Methods And Compositions For Cancer Therapies That Include Delivery Of Halogenated Thymidines And Thymidine Phosphorylase Inhibitors In Combination With RadiationSHUTTLE PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 0475US12077515B2Selective histone deacetylase inhibitors for the treatment of human diseaseSHUTTLE PHARMACEUTICALS INC·Filed 2022·Granted Sep 3, 2024·0 cites·20 claims
- 0574US2022055988A1Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereofSHUTTLE PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 0669US2020317611A1Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereofSHUTTLE PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 0769US2024174630A1Selective histone deacetylase inhibitors for the treatment of human diseaseSHUTTLE PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 0868US10730834B2Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereofSHUTTLE PHARMACEUTICALS INC·Filed 2017·Granted Aug 4, 2020·0 cites·10 claims
- 0967US11654157B2Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorylase inhibitors in combination with radiationSHUTTLE PHARMACEUTICALS INC·Filed 2018·Granted May 23, 2023·0 cites·10 claims
- 1065US11407723B2Selective histone deacetylase inhibitors for the treatment of human diseaseSHUTTLE PHARMACEUTICALS INC·Filed 2019·Granted Aug 9, 2022·0 cites·5 claims
- 1164US11584733B2Selective histone deacetylase inhibitors for the treatment of human diseaseSHUTTLE PHARMACEUTICALS INC·Filed 2021·Granted Feb 21, 2023·0 cites·20 claims
- 1263US10745352B2Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereofSHUTTLE PHARMACEUTICALS INC·Filed 2016·Granted Aug 18, 2020·0 cites·4 claims
- 1348US11034667B2Selective histone deacetylase inhibitors for the treatment of human diseaseSHUTTLE PHARMACEUTICALS INC·Filed 2018·Granted Jun 15, 2021·0 cites·6 claims
Join the waitlist — get patent alerts
Get an alert when SHUTTLE PHARMACEUTICALS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →